RxDoctor Payments Data

Michael Lee, MD

Family Medicine · San Diego, CANPI 1013114933

Payments from drug & device makers

$2,986in general payments, 2019–2025

Across 111 payments — averaging $26.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$495
  • AbbVie$305
  • Lilly USA, LLC$293
  • Pfizer$215
  • Sanofi$189
  • Merck$188
  • plus $1K from 24 others

What the payments were for

  • Food & beverage$2,986100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,986 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$147,753
Medicare patients
303
Services billed
1,907

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin34$42,896
JanuviaSitagliptin Phosphate24$37,337
EliquisApixaban27$29,635
FarxigaDapagliflozin Propanediol17$29,070
TrulicityDulaglutide16$28,465
TradjentaLinagliptin15$21,371
Atorvastatin Calcium360$3,216
Tadalafil19$2,471
Levothyroxine Sodium163$2,367
Tamsulosin Hcl99$1,461
Rosuvastatin Calcium93$1,423
Losartan Potassium135$1,256
SynthroidLevothyroxine Sodium17$1,061
Pantoprazole Sodium84$1,023
Nifedipine ErNifedipine24$956

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$81$64,26649 claims
MerckJanuvia$188$37,33724 claims
PfizerEliquis$215$29,63527 claims
AstraZenecaFarxiga$495$29,07017 claims
Lilly USA, LLCTrulicity$293$28,46516 claims
AbbVieSynthroid$305$1,06117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.

Other family medicine in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →